Deutsche Bank initiated coverage on Medpace with a new price target
$MEDP
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Deutsche Bank initiated coverage of Medpace with a rating of Hold and set a new price target of $395.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/23/2024 | $413.00 → $349.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/27/2024 | $420.00 → $350.00 | Buy → Neutral | UBS |
| 9/25/2024 | $415.00 → $345.00 | Buy → Hold | Jefferies |
| 8/1/2024 | $415.00 | Hold | Truist |
| 5/29/2024 | $452.00 | Buy | TD Cowen |
| 5/28/2024 | $435.00 | Buy | Mizuho |
| 4/23/2024 | $340.00 → $450.00 | Hold → Buy | Jefferies |
10-Q - Medpace Holdings, Inc. (0001668397) (Filer)
8-K - Medpace Holdings, Inc. (0001668397) (Filer)
144/A - Medpace Holdings, Inc. (0001668397) (Subject)
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq
Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $533.7 million in the third quarter of 2024, representing a decrease of 12.7% from net new business awards of $611.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.00x. Third quarter of 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the comparable prior-year period. Net income margin was 18.1% and 14.3% for the third quarter of 2024 a
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq
Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $533.7 million in the third quarter of 2024, representing a decrease of 12.7% from net new business awards of $611.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.00x. Third quarter of 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the comparable prior-year period. Net income margin was 18.1% and 14.3% for the third quarter of 2024 a
Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
4 - Medpace Holdings, Inc. (0001668397) (Issuer)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)
Robert W. Baird downgraded Medpace from Outperform to Neutral and set a new price target of $349.00 from $413.00 previously
Redburn Atlantic initiated coverage of Medpace with a rating of Buy
UBS downgraded Medpace from Buy to Neutral and set a new price target of $350.00 from $420.00 previously